Precision medicine firm WuXi NextCODE has entered into an agreement with Shanghai-based Children's Hospital of Fudan University (CHFU) to provide genomic testing capabilities for rare diseases in China.

Under the deal, WuXi has agreed to provide the full range of its genome testing infrastructure to CHFU, including CLIA sequencing, massively scalable informatics and interpretation tools, as well as clinical genetics expertise.

The deal will allow CHFU to provide Chinese rare disease patients the same sequence-based diagnostics currently available to patients in the US and Europe through partners Boston Children’s Hospital and Genomics England.

CHFU president Guoying Huang said: "Looking for the genomics infrastructure that could deliver the best results for our patients, we saw that our colleagues at Harvard Medical School and other leading institutions were choosing WuXi NextCODE."

WuXi NextCODE president and COO co-founder Hannes Smarason said: "China is central to that strategy, and we couldn’t have a better partner than Fudan Children’s for realizing it and giving thousands of young patients and their families the best diagnostics and treatment options for inherited rare disorders."

WuXi NextCODE offers comprehensive and integrated capabilities for using the genome to better diagnose disease and create better medicine, as well as full range of sequencing services through CLIA-certified laboratory.

Established in 1952, CHFU is a tertiary academic medical center that offers pediatric patient care, education and research.